Physician profile
Jaclyn E Hone
NPI 1982644506
$2,848.99
in general payments reported to CMS, 2019-2025
21 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $495 · 2021: $460 · 2022: $344 · 2023: $165 · 2024: $190 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $610.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $598.06 | 2019-2024 | Xifaxan |
| Novo Nordisk INC | $492.83 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $377.89 | 2019-2022 | |
| Abbvie INC. | $343.03 | 2019-2025 | |
| Amarin Pharma, INC. | $236.54 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $152.47 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $144.09 | 2019-2020 | |
| Allergan, INC. | $93.21 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.44 | 2019-2020 | |
| Amgen INC. | $79.18 | 2019-2020 | |
| Philips North America LLC | $44.09 | 2024 | (Ck6) Holter, (Ck7) Extended Holter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.74 | 2024-2025 | Caplyta |
| Aytu Biopharma, INC. | $24.85 | 2019 | |
| Eisai INC. | $24.46 | 2021 | |
| Astellas Pharma US INC | $24.24 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $18.65 | 2019 | |
| Shire North American Group INC | $17.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.27 | 2019 | |
| Merck Sharp & Dohme LLC | $12.76 | 2019 | |
| Pfizer INC. | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaclyn Hone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.